A Study of Remitoro in Participants With Recurrent or Refractory Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma (All Case Study)

NCT05137847 · clinicaltrials.gov ↗

COMPLETED

Status

118

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma, T-cell, Peripheral
Lymphoma, T-cell, Cutaneous

Interventions

DRUG: Remitoro

Sponsor

Eisai Inc.